secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2023-09-12T23:59:59+00:00
Accession:  0001104659-23-099872
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis Pharma initiates Phase 1a trial of NXP900 for advanced solid tumors
----------------------------------------------------------------------------

- Phase 1a dose-escalation study evaluates safety, tolerability, and PK of NXP900 in advanced solid tumor patients.
- NXP900 is a novel SRC/YES1 kinase inhibitor with low nanomolar IC50 (YES1: 0.5nM, SRC: 2.4nM).
- Preclinical models showed robust single-agent anti-cancer activity across several solid tumor types.
- CEO Ron Bentsur highlights NXP900's unique mechanism and target specificity versus multi-kinase inhibitors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465923099872/0001104659-23-099872-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465923099872/tm2325910d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-099872

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer